-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Patients with resoic colorectal cancer (CRC) have few effective treatment options.
recently, a study published in British Journal of Cancer, an authoritative journal in the field of oncology, was designed to test the efficacy of metformin and elixir combination therapy in such patients.
researchers conducted a two-phase single-group trial in which patients were given 2,500 mg of metformin daily or oral, and 125 mg/m2 of intravenously, once a week.
the study was the disease control rate at 12 weeks based on the Version 1.1 Solid Tumor Response Assessment Standard.
between December 2015 and January 2018, researchers recruited 41 patients.
17 patients (41 percent) reached the main end of disease control in 12 weeks.
participants had a non-progressed lifetime of 3.3 months (95% CI for 2.0-4.5 months) and a total participant survival period of 8.4 months (95% CI for 5.9-10.8 months).
in the multivariate model, both RAS mutation status and disease control at 12 weeks affected the participants' total survival rate (HR was 2.28, 95% CI was 1.12-4.7, p=0.02; HR was 0.21, 95% CI was 0.08-0.5, p=0.001).
most common adverse events were diarrhoea (29.2% of participants had level 3 diarrhea).
in this trial, patients with resophedic CRC were treated with metformin and erythyroid to achieve disease control.
further optimized diarrhea control tests are needed to confirm these results.